pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ATOMOXETINE
drug
save

atomoxetine

Phase 1updated 3mo ago
by Hyloris Pharmaceuticals SA
Phase 1
community read0 votes

🐶 often sniffed alongside

top 6
  • companyGlenmark Pharmaceuticals Ltd56 co-mentions · 14 sources
  • tagRecall28 co-mentions · 14 sources
  • companyNorthstar Rx LLC14 co-mentions · 7 sources
  • tagApproval2 co-mentions · 1 sources
  • drugatomoxetine hydrochloride1 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying atomoxetine

  • phase2Parallel Arm Trial of AD109 and AD504 In Patients With OSAcompletedn=294
  • phase4A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)completedn=396
  • —A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetaminecompletedn=430,000
  • phase3Continuation Protocol for Obstructive Sleep Apnea (OSA)enrolling by invitationn=1,280
  • —A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japancompletedn=17,418
  • phase2Crossover Trial of AD036 in Obstructive Sleep Apneacompletedn=62
  • phase2Trial of AD113 and Atomoxetine in OSA Patients With Hypertensioncompletedn=21

News(2)

  • Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
    Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
    fiercebiotech · 14d ago
  • Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
    Apnimed has detailed its plans for an initial public offering, with the biotech intending to raise as much as $160 million to fund the launch of its sleep apnea pill.
    fiercebiotech · 18d ago
brand
ATOMOXETINE
generic
atomoxetine [INN]
indication
Attention Deficit Hyperactivity Disorder (ADHD)
phase
phase_1
Data sources
ClinicalTrials.gov
last refreshed 50m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?